Products
Afimkibart Biosimilar Monoclonal Antibody (TL1A) for Research
Cat No.: GMP-Bios-INN-1068
Anti-TNFSF15/TL1A/VEGI therapeutic antibody (Pre-made Afimkibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Afimkibart (development code PF 6480605) is a monoclonal antibody targeting TNFSF15 (TL1A). It is developed by Pfizer and Roche for ulcerative colitis, Crohn's disease, inflammatory bowel diseases. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1068-1mg | 1mg | 3090 |
| GMP-Bios-INN-1068-10mg | 10mg | |
| GMP-Bios-INN-1068-100mg | 100mg | |
| GMP-Bios-INN-1068-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Afimkibart biosimilar, Whole mAb, Anti-TNFSF15/TL1A/VEGI Antibody: Anti-TNFSF15/Tumor necrosis factor ligand superfamily member 15/TNF ligand-related molecule 1/Vascular endothelial cell growth inhibitor therapeutic antibody |
| INN Name | Afimkibart |
| Target | TNFSF15/TL1A/VEGI |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Pfizer;Roche |
| Conditions Approved | na |
| Conditions Active | Ulcerative colitis;Crohn's disease;Inflammatory bowel diseases |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
